Finally, CTLA-4 therapy has been found to cause hypophysitis, likely due to enhanced complement-mediated inflammation due to direct binding of anti-CTLA-4 antibody with CTLA-4 expressed on normal pituitary tissue (93). Here, CTLA4 is linked to hypophysitis.